

# Sequence-Specific DNA Binding by the $\alpha$ NAC Coactivator Is Required for Potentiation of c-Jun-Dependent Transcription of the Osteocalcin Gene

Omar Akhouayri,<sup>1</sup> Isabelle Quélo,<sup>1†</sup> and René St-Arnaud<sup>1,2\*</sup>

Genetics Unit, Shriners Hospital for Children, Montréal, Québec, Canada H3G 1A6,<sup>1</sup> and Departments of Medicine, Surgery, and Human Genetics, McGill University, Montréal, Québec, Canada H3A 2T5<sup>2</sup>

Received 7 September 2004/Returned for modification 14 October 2004/Accepted 11 January 2005

Since the c-Jun coactivator  $\alpha$ NAC was initially identified in a differential screen for genes expressed in differentiated osteoblasts, we examined whether the osteocalcin gene, a specific marker of terminal osteoblastic differentiation, could be a natural target for the coactivating function of  $\alpha$ NAC. We had also previously shown that  $\alpha$ NAC can specifically bind DNA *in vitro*, but it remained unclear whether the DNA-binding function of  $\alpha$ NAC is expressed *in vivo* or if it is required for coactivation. We have identified an  $\alpha$ NAC binding site within the murine osteocalcin gene proximal promoter region and demonstrated that recombinant  $\alpha$ NAC or  $\alpha$ NAC from ROS17/2.8 nuclear extracts can specifically bind this element. Using transient transfection assays, we have shown that  $\alpha$ NAC specifically potentiated the c-Jun-dependent transcription of the osteocalcin promoter and that this activity specifically required the DNA-binding domain of  $\alpha$ NAC. Chromatin immunoprecipitation confirmed that  $\alpha$ NAC occupies its binding site on the osteocalcin promoter in living osteoblastic cells expressing osteocalcin. Inhibition of the expression of endogenous  $\alpha$ NAC in osteoblastic cells by use of RNA interference provoked a decrease in osteocalcin gene transcription. Our results show that the osteocalcin gene is a target for the  $\alpha$ NAC coactivating function, and we propose that  $\alpha$ NAC is specifically targeted to the osteocalcin promoter through its DNA-binding activity as a means to achieve increased specificity in gene transcription.

The calcium-binding osteocalcin protein is a terminal differentiation marker of the osteoblastic lineage. Dissection of the regulatory sequences controlling the osteoblast-specific expression of the osteocalcin gene has significantly improved our understanding of the molecular mechanisms regulating transcription during skeletogenesis, for example, through identification of Runx2/Cbfa1 as an osteoblast differentiation factor (22, 25). Characterization of osteocalcin gene transcription has uncovered several regulatory elements in the osteocalcin promoter (26), including binding sites for the AP-1 family of transcription factors (2, 5, 16, 28, 33–35, 40, 41).

The AP-1 family member c-Jun interacts with coactivators to potentiate transcription. One such coactivator has been characterized as  $\alpha$ NAC (30, 36–38). The  $\alpha$ NAC protein, first identified as a regulator of protein translation (45), was subsequently shown to also function as a transcriptional coactivator by potentiating the activities of the chimeric Gal4-VP16 activator (47) and of c-Jun homodimers (30, 36–38).  $\alpha$ NAC provides a protein bridge between c-Jun and the basal transcriptional machinery by contacting the general transcription factor TBP (47). This stabilizes the c-Jun dimers on their cognate response element and results in enhanced transcription rates (30). In the course of those studies, it was shown that  $\alpha$ NAC can specifically bind DNA, although it does not act as a transcription factor (48). It remained unclear whether the DNA-

binding function of  $\alpha$ NAC is expressed or if it is masked *in vivo* and whether it is required for the coactivating activity of  $\alpha$ NAC.

The targeting of coactivators to particular promoters through sequence-specific DNA binding is a means to achieve increased specificity in gene transcription. For example, the B-cell specificity of octamer promoters is due to the interaction of the ubiquitous Oct-1 or lymphoid-specific Oct-2 factors with the B-cell-specific coactivator Bob-1 (24). To prevent the widespread activation of any promoter recognized by Oct-1 or Oct-2, Bob-1 activity is restricted to particular sites by virtue of its sequence-specific DNA-binding activity (9, 18). Similarly, certain TAF coactivators have been shown to bind core promoter elements, including the initiator region and the downstream promoter element (17).

Considering that we cloned  $\alpha$ NAC as a differentially expressed protein in differentiated osteoblasts (30, 47), we examined whether the osteocalcin gene, a specific marker of terminal osteoblastic differentiation, could be a natural target for the coactivating activity of  $\alpha$ NAC. We have identified an  $\alpha$ NAC binding site within the murine osteocalcin gene proximal promoter region and demonstrated that recombinant  $\alpha$ NAC or  $\alpha$ NAC from nuclear extracts of osteoblastic ROS17/2.8 cells can specifically bind this element. Using transient transfection assays, we have shown that  $\alpha$ NAC potentiated the c-Jun-dependent transcription of the osteocalcin promoter and that this activity specifically required the DNA-binding domain of  $\alpha$ NAC or the intact  $\alpha$ NAC binding site within the promoter region. Using chromatin immunoprecipitation, we observed that  $\alpha$ NAC occupied its cognate binding site on the osteocalcin promoter in differentiated osteoblastic cells that express osteocalcin. Finally, inhibition of endogenous  $\alpha$ NAC expression by

\* Corresponding author. Mailing address: Genetics Unit, Shriners Hospital for Children, 1529 Cedar Avenue, Montréal, Québec, Canada H3G 1A6. Phone: (514) 282-7155. Fax: (514) 842-5581. E-mail: rst-arnaud@shriners.mcgill.ca.

† Present address: Aventis Pharma Deutschland GmbH, Industriepark Hoechst, D-65926 Frankfurt am Main, Germany.

use of siRNAs affected osteocalcin promoter activity in osteoblastic cells. Our results show that the osteocalcin gene is a natural target for the  $\alpha$ NAC coactivating function and that  $\alpha$ NAC is specifically targeted to the osteocalcin promoter, presumably as a means to achieve increased specificity in gene transcription.

## MATERIALS AND METHODS

**Abbreviations.**  $\alpha$ NAC, nascent polypeptide associated complex and coactivator alpha; Runx2/Cbfa1, Runt family member  $\times$ 2/Core-binding factor alpha 1; AP-1, activating protein 1; Oct, octamer-binding protein; Bob-1, B-cell Oct-binding protein 1; OCN, osteocalcin; mmp-9, matrix metalloproteinase 9; OC box 1, osteocalcin box 1; ChIP, chromatin immunoprecipitation; DBD, DNA-binding domain; siRNA, small interfering RNA; TBP, TATA-binding protein; TAF, TBP-associated factors; EMSA, electrophoretic mobility shift assay; TBE, Tris-borate-EDTA; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis.

**Expression vectors and reporter plasmids.** The p1316OG2-Luc reporter construct (herein referred to as OCN-Luc) (13) and the pCMV-Osf2 expression vector (14) (for expression of full-length Runx2/Cbfa1) were generous gifts from Gérard Karsenty (Baylor College of Medicine, Houston, TX). The mmp-9 pGL3 reporter (MMP9-Luc), which contains the proximal 670 bp of the mmp-9 gene promoter driving luciferase (19), was provided by Shoukat Dedhar (University of British Columbia, Vancouver, British Columbia, Canada). To engineer the OCN-Luc  $\Delta$ BDG reporter, p1316OG2-Luc was digested at a unique Bst-AP1 restriction site within the osteocalcin promoter. The plasmid was then digested with Bal-31 nuclease following the manufacturer's procedure (New England Biolabs, Pickering, Ontario, Canada). The Bal-31-digested blunt-ended DNA fragments were self-ligated and used to transform *Escherichia coli*. Clones in which the  $\alpha$ NAC binding site (positions -35 to -45 relative to the transcription start site) was deleted (plasmid OCN-Luc  $\Delta$ BDG; the deletion covered from -32 to -60) were confirmed by direct DNA sequencing. Site-specific mutagenesis of the  $\alpha$ NAC binding site within the murine osteocalcin promoter fragment (GCACgGTAG [lowercase indicates mutated residues]; OCN-Luc mut BDG reporter) was performed by NorClone Biotech Laboratories (London, Ontario, Canada) using inverse PCR. The expression vectors for the Flag epitope-tagged full-length  $\alpha$ NAC (pSI-NAC-Flag) (36) and for full-length c-Jun (pCI-cJun) (38) have been described previously. The cDNA for the  $\Delta$ 69-80 deletion mutant ( $\alpha$ NAC $\Delta$ 69-80) was obtained by PCR cloning and inserted in-frame into pSI-Flag (36) to yield the pSI- $\alpha$ NAC $\Delta$ 69-80-Flag expression vector.

**Transfections.** COS-7 African green monkey cells were transfected using Lipofectamine reagent as described previously (36). Transfections utilized 300 ng of pCi-cJun alone or in combination with 300 ng of pSI-NAC-Flag or pSI- $\alpha$ NAC $\Delta$ 69-80-Flag. In one series of transfections, pCi-cJun was replaced by pCMV-Osf2. One hundred nanograms of reporter plasmids was used, and 40 ng of pSV6tk-CAT (11) was added to each sample as a control of transfection efficiency. All transfections were conducted in triplicate, and values are reported as means  $\pm$  standard errors of the means. Statistical analysis was performed using analysis of variance and the Tukey or Bonferroni posttests. *P* values of <0.05 were accepted as significant. The expression level of transfected proteins was controlled by immunoblotting following immunoprecipitation with anti-Flag or anti-c-Jun antibodies (38).

**EMSA.** Complementary oligonucleotides corresponding to the putative  $\alpha$ NAC binding site within the murine osteocalcin proximal promoter region (5'-GAGAGCAGAGATAGCCGA-3', positions -49 to -32 relative to the transcription start site [the putative binding site is shown in italics]) were synthesized with an overhang, annealed, and labeled with <sup>32</sup>P-labeled deoxynucleoside triphosphates by Klenow fill-in using standard protocols (3). One probe (see Fig. 2C) covered the  $\alpha$ NAC binding site and the OC box 1 of the osteocalcin promoter, positions -103 to -30 relative to the transcription start site. Competitions used unlabeled double-stranded oligonucleotides corresponding to the previously identified  $\alpha$ NAC binding site (5'-GAGACGACACACAGGCCGA-3'; 1 $\times$  NAC) (48) or the mutated osteocalcin sequence (5'-GAGAGCACgGTAGCCGA-3'; mut).

The recombinant  $\alpha$ NAC proteins (wild-type and  $\Delta$ 69-80) were purified using NEB's IMPACT system as described previously (38). ROS17/2.8 nuclear extracts were prepared following the technique of Dignam et al. (12) as detailed elsewhere (7). Purified, recombinant c-Jun protein was purchased from Promega (Madison, WI).

Recombinant proteins or nuclear extracts were incubated for 30 min at 4°C in 20  $\mu$ l of binding buffer [100 mM HEPES, pH 7.5, 20 mM MgCl<sub>2</sub>, 500 mM NaCl, 2% NP-40, 10 mM dithiothreitol, 10 mM EDTA, 100 ng of poly(dI-dC), 30%

glycerol]. Labeled probe (5,000 dpm) was added to the binding reaction mixture. For competition experiments, the binding reaction was incubated with excess unlabeled 1 $\times$  NAC or mut oligonucleotides. For supershift assays, anti- $\alpha$ NAC antibody (48) or anti-c-Jun antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA) was added to the binding reaction for 15 min prior to the addition of the labeled probe. The bound mixtures were size fractionated on a nondenaturing 6% polyacrylamide gel at 140 V for 4 h in 0.5 $\times$  TBE buffer. The gels were subsequently dried and autoradiographed.

**ChIP.** MC3T3-E1 cells (44) were plated on 100-mm-diameter dishes for 14 or 21 days in mineralizing media (10 mM  $\beta$ -glycerophosphate and 50  $\mu$ g/ml ascorbic acid). Cells were then cross-linked by adding formaldehyde (1%, 20 min) with gentle agitation. The cross-linking was stopped by the addition of glycine to a final concentration of 125 mM for 10 min. The cells were then washed three times with ice-cold phosphate-buffered saline, scraped, and collected by centrifugation in 1 ml phosphate-buffered saline plus protease inhibitors (1  $\mu$ g/ml leupeptin, 1  $\mu$ g/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride). The cell pellet was resuspended for 10 min on ice in lysis buffer (5 mM PIPES [piperazine-*N,N'*-bis(2-ethanesulfonic acid)], pH 8.0, 85 mM KCl, and 0.5% NP-40, with protease inhibitors as described above). The nuclei were pelleted by centrifugation (5,000 rpm, 5 min), resuspended in 1.5 ml of nuclear lysis buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS, and protease inhibitors), and incubated on ice for 10 min.

To reduce the length of the chromatin fragments to approximately 600 bp, the extract was sonicated with a Sonic Dismembrator (model 500, Fisher Scientific Ltd., Nepean, Ontario, Canada), using four 15-s pulses at 30% of maximal power. After centrifugation (12,000  $\times$  g, 10 min, 4°C), the supernatant containing the chromatin was collected. Cross-linked extracts were diluted fivefold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, protease inhibitors). Immunoprecipitations were performed with Sepharose-conjugated anti-Flag monoclonal antibody (Sigma-Aldrich, St. Louis, MO), anti- $\alpha$ NAC polyclonal antibody (48), anti-IgG-agarose (as a negative control), or anti-Runx2/Cbfa1 polyclonal antibody (Santa Cruz). The immune complexes (anti- $\alpha$ NAC and anti-Runx2) were recovered with the addition of 150  $\mu$ l of protein A-Sepharose beads and a subsequent incubation for 3 h at 4°C with agitation. The complexes were washed for 5 min with 1 ml of each of the following solutions: low-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), high-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), and LiCl wash buffer (250 mM LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0). Finally, they were washed twice in 1 $\times$  Tris-EDTA buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA).

The protein-DNA complexes were eluted by two incubations with 250  $\mu$ l of elution buffer (100 mM NaHCO<sub>3</sub>, 1% SDS) with agitation and then centrifuged (10,000  $\times$  g for 3 min). To reverse cross-linking, the supernatant was collected and incubated with 1  $\mu$ l of 10-mg/ml RNaseA in 300 mM NaCl at 65°C for 4 h. Then, the proteins were digested with 200  $\mu$ g of proteinase K per ml for 1 h at 45°C. The DNA was precipitated overnight with ethanol at -20°C. DNA fragments were purified with a QIAquick Spin instrument (QIAGEN Inc.-Canada, Mississauga, Ontario, Canada). The sequences of the primers used were as follows. For  $\alpha$ NAC forward, 5'-AGGCAGCTGCAATCACCA-3' (beginning at nucleotide -153 of the murine osteocalcin promoter sequence) was used, and for  $\alpha$ NAC reverse, 5'-GCACCCTGCAGCATCCA-3' (position -2) was used. For Runx2/Cbfa1, the primers used were as published by Shen et al. (42): forward, 5'-AAATGAGGACATTACTGAACACTCC-3' (position -459); and reverse, 5'-CCAAGGATGCTGTGGTTGGTGAT-3' (position -118).

**Northern blot assay.** Total RNA was isolated with the Trizol reagent (Life Technologies Inc., Burlington, Ontario, Canada), and Northern blots were performed using a standard methodology. The probe used was the 470-bp EcoRI-PstI fragment from the mouse osteocalcin cDNA (8).

**RNA interference.** A clone of MC3T3-E1 preosteoblasts showing high differentiation/mineralization potential and stably transfected with 1.3 kb of the mouse osteocalcin gene promoter driving expression of luciferase (46), a generous gift of Renny T. Franceschi (University of Michigan), was cultured at confluence for 7 days in the presence of G418. The cells were then passaged onto gelatin-coated wells at 20,000 cells/well in 24-well plates. The following day, the cells were transfected with 100 nM of siRNA directed against  $\alpha$ NAC (catalog number 156855; Ambion Inc., Austin, TX) using 2.5  $\mu$ l of siPORT Amine (Ambion) according to the manufacturer's instructions. Control wells were treated with the siPORT reagent only or were transfected with siRNA control no. 1, a sequence that shows no homology to any inventoried gene in the mouse or human databases (Ambion). The transfection mixture was left on the cells for 8 h, and then 1 ml of complete medium was added. RNA was harvested at 32 h posttransfection using the RNAqueous-4PCR kit (Ambion). The RNA was re-

verse-transcribed into cDNA using a High-Capacity cDNA Archive Kit per the manufacturer's recommendations (Applied Biosystems, Foster City, CA). Real-time PCR amplification was performed on an Applied Biosystems 7700 instrument using the TaqMan Universal PCR Master Mix (Applied Biosystems) and specific TaqMan assays for  $\alpha$ NAC, OCN, and GAPDH. The expression level of each mRNA was quantified by the  $\Delta\Delta C_T$  method (User bulletin no. 2, ABI Prism 7700 sequence detection system) and normalized to GAPDH levels. For luciferase activity, cell lysates were prepared in the reporter gene assay lysis buffer (Roche Molecular Biochemicals, Laval, Quebec, Canada). One hundred microliters of cell lysate was used for single luciferase reporter assays following the manufacturer's instructions (Promega). Luciferase activity was measured with a Sirius luminometer (Berthold Detection Systems GmbH, Pforzheim, Germany). The expression level detected in cells treated with the transfection reagent alone was arbitrarily given a value of 1. Statistical significance was determined by analysis with an unpaired, one-tailed Student's *t* test for two-group comparison or by analysis of variance followed by the Dunnett's posttest for multiple group comparison. *P* values of <0.05 were accepted as significant.

## RESULTS

**$\alpha$ NAC specifically potentiates c-Jun-dependent transcription from the mouse osteocalcin promoter.** Since we identified the c-Jun coactivator  $\alpha$ NAC as a differentially expressed gene product in terminally differentiated mouse osteoblasts (30, 47), we tested whether the osteocalcin gene, a marker of the mature osteoblastic phenotype and an AP-1 target (2, 5, 16, 28, 33–35, 40, 41), would respond to the coactivating activity of  $\alpha$ NAC. A reporter construct in which the luciferase gene was placed downstream from the murine osteocalcin gene promoter (13) was cotransfected with expression vectors for c-Jun and/or  $\alpha$ NAC. Figure 1 shows that c-Jun activated transcription from the mouse osteocalcin gene promoter (bar 2) and that this effect was potentiated by cotransfection with full-length, wild-type  $\alpha$ NAC (bar 4). Since it is a coactivator, not a transcription factor, expression of  $\alpha$ NAC by itself did not influence reporter gene expression (bar 3), as previously observed with other promoters (36, 48). The coactivating activity of  $\alpha$ NAC was specific to c-Jun, as cotransfecting  $\alpha$ NAC with Runx2/Cbfa1, a key regulator of osteocalcin gene transcription (14, 22, 27), had no effect on Runx2/Cbfa1-mediated transcription (Fig. 1, bars 5 and 6). The expression of the transfected FLAG-NAC fusion protein was monitored by immunoblotting using the anti- $\alpha$ NAC antibody (48), which also detects the endogenous protein (Fig. 1B). Since each transfection was performed at least three times in triplicate with identical results, we are confident that the lack of coactivation activity of  $\alpha$ NAC with Runx2/Cbfa1 was not due to the somewhat lower expression levels observed in the immunoblot shown in Fig. 1B. We conclude that  $\alpha$ NAC specifically potentiates the c-Jun-mediated transcription of the osteocalcin gene.

**$\alpha$ NAC specifically binds the osteocalcin proximal promoter region.** We have previously reported that  $\alpha$ NAC can bind the degenerate sequence 5'-C/G C/G A C/G A C/G A nnn G-3', where n is any nucleotide (48). We identified a matching sequence between positions -35 and -45 of the mouse osteocalcin promoter (5'-GCACAGagtaG-3') and used EMSA to determine whether  $\alpha$ NAC could specifically bind this element. A labeled, double-stranded probe corresponding to positions -49 to -32 relative to the osteocalcin transcription start site was synthesized and used in EMSA with purified recombinant  $\alpha$ NAC. Figure 2A shows that the recombinant protein formed a strong complex with the labeled probe (lane 3) that was supershifted in the presence of a specific anti- $\alpha$ NAC antibody




FIG. 1.  $\alpha$ NAC specifically potentiates the transcription of the osteocalcin gene promoter by c-Jun. (A) COS-7 cells were transiently transfected with an osteocalcin-luciferase reporter and expression vectors for c-Jun,  $\alpha$ NAC, or Runx2/Cbfa1, alone or in combinations. c-Jun induced the transcription of the reporter, and this induction was potentiated by  $\alpha$ NAC. The coactivating function of  $\alpha$ NAC was specific to c-Jun, as  $\alpha$ NAC expression did not affect Runx2/Cbfa1-activated osteocalcin gene transcription. The expression level detected in cells transfected with the reporter construct alone was arbitrarily given a value of 1. Results are means  $\pm$  standard errors of the means of three independent transfections performed in triplicate. \*, *P* < 0.05; \*\*\*, *P* < 0.001. (B) Immunoblot probed with the anti- $\alpha$ NAC antibody that shows expression levels of endogenous and FLAG-tagged  $\alpha$ NAC. The order of the numbered tracks corresponds to the order of the bars in panel A.

(lane 4) (48). A less intense complex with slower electrophoretic mobility that was not as affected by the antibody was also observed. This complex could be due to differentially phosphorylated forms of  $\alpha$ NAC (36, 37). Preimmune serum or an excess of unlabeled mutated oligonucleotide did not influence binding (lanes 5, 6), while increasing amounts of an unlabeled oligonucleotide corresponding to the previously characterized  $\alpha$ NAC binding site (48) efficiently competed binding of both complexes (lanes 7 to 9). An unrelated protein (maltose-binding protein) purified using the same system that was used for the purification of recombinant  $\alpha$ NAC proteins did not bind the probe (lane 2), confirming that the binding activity was not due to a contaminant from the protein purification system. Nuclear extracts from the osteoblastic cell line ROS 17/2.8 also formed a complex with the labeled probe that was specifically but not completely supershifted by the anti- $\alpha$ NAC antibody, demonstrating that nuclear  $\alpha$ NAC from osteoblasts could bind the osteocalcin sequence (Fig. 2B, lanes 2 to 4).

We have engineered a series of C-terminal and internal deletion mutants of the  $\alpha$ NAC protein (37, 38) and tested them for DNA-binding activity with EMSA (data not shown).




FIG. 2.  $\alpha$ NAC and c-Jun bind the osteocalcin proximal promoter. EMSAs using a probe from the murine osteocalcin gene and purified recombinant  $\alpha$ NAC (A), nuclear extracts (NE) from ROS 17/2.8 cells (B), or recombinant c-Jun and recombinant  $\alpha$ NAC (C). In panel A, a specific complex can be detected ( $\alpha$ NAC arrow) that was “supershifted” in the presence of anti- $\alpha$ NAC antibodies (Ab). Preimmune serum (Serum) did not influence complex migration. The complex was competed with increasing amounts of the canonical  $\alpha$ NAC binding site (1xNAC) but not with a mutated sequence (mut). DBD-deleted  $\alpha$ NAC ( $\Delta$ 69-80) did not bind the probe (lane 10). Panel B shows that  $\alpha$ NAC from ROS 17/2.8 osteoblastic cells bound the probe. The complex was specifically but not completely supershifted by the anti- $\alpha$ NAC antibody (Ab). In panel C, the probe used covered positions  $-103$  to  $-30$  of the osteocalcin promoter and encompassed the  $\alpha$ NAC binding site and the OC box 1 (34). Recombinant c-Jun did not bind the probe by itself (lane 2), but a complex containing c-Jun could be detected (c-Jun arrow) when the probe was incubated with both c-Jun and  $\alpha$ NAC (lanes 4 and 5).

We found that deleting residues 69 to 80 of the 215-amino-acid  $\alpha$ NAC protein abrogated the ability of the mutated protein ( $\alpha$ NAC $\Delta$ 69-80) to bind DNA (Fig. 2A, lane 10). These experiments mapped the  $\alpha$ NAC DNA-binding domain to residues 69 to 80 and showed that recombinant  $\alpha$ NAC, as well as  $\alpha$ NAC

from osteoblastic nuclear extracts, could specifically bind the osteocalcin proximal promoter region in EMSA.

We also tested the binding of recombinant c-Jun to the mouse osteocalcin promoter. We used an oligonucleotide probe covering residues  $-103$  to  $-30$  of the mouse promoter. This probe included the  $\alpha$ NAC binding site ( $-45$  to  $-35$ ) and a sequence that is 100% homologous to the OC box 1 from the rat osteocalcin gene promoter ( $-99$  to  $-76$ ) (13, 34). The rat OC box 1 was shown to bind Fos/Jun AP-1 complexes (34). As previously reported (34), c-Jun homodimers did not bind this element (Fig. 2C, lane 2). The probe efficiently bound recombinant  $\alpha$ NAC (lane 3). Interestingly, when the probe was incubated with both  $\alpha$ NAC and c-Jun, a novel complex formed (lane 4). This complex contained c-Jun, since it was supershifted by an anti-c-Jun antibody (lane 5). We interpret this result to mean that  $\alpha$ NAC can stabilize the binding of c-Jun homodimers to the osteocalcin promoter, as was previously described for the AP-1 site from the metallothionein-IIA promoter (30).

**$\alpha$ NAC must bind the osteocalcin promoter to coactivate c-Jun-dependent osteocalcin gene transcription.** Transient transfection assays were used to determine the importance of the binding of  $\alpha$ NAC to the osteocalcin promoter for its coactivating activity. In the first series of experiments, the activity of the DBD-deleted mutant ( $\alpha$ NAC $\Delta$ 69-80) was compared to the activity of intact  $\alpha$ NAC. Figure 3A shows that contrary to its wild-type counterpart,  $\alpha$ NAC $\Delta$ 69-80 could not potentiate c-Jun-mediated osteocalcin gene transcription. Both  $\alpha$ NAC and  $\alpha$ NAC $\Delta$ 69-80 were efficiently expressed in those experiments (Fig. 3B, second panel). The FLAG-tagged  $\alpha$ NAC proteins were expressed at levels similar to that of endogenous  $\alpha$ NAC (Fig. 3B, third panel) (note that FLAG- $\alpha$ NAC $\Delta$ 69-80 comigrates with endogenous  $\alpha$ NAC, and thus the anti- $\alpha$ NAC antibody recognizes both proteins at the same position in the gel).

The  $\alpha$ NAC binding element was then mutated or deleted from the osteocalcin promoter. While c-Jun could still increase transcription from both mutated reporters (OCN-Luc  $\Delta$ BDG and OCN-Luc mut BDG; Fig. 4A and B, respectively), wild-type  $\alpha$ NAC could not potentiate c-Jun-dependent expression of the reporter gene when its binding site was mutated (Fig. 4B, bar 8) or removed from the osteocalcin promoter (Fig. 4A, bar 6). Taken together, those data show that  $\alpha$ NAC must interact with the promoter to coactivate osteocalcin gene expression induced by c-Jun.

**The  $\alpha$ NAC DNA-binding domain is specifically required for osteocalcin expression.** To determine whether  $\alpha$ NAC must always bind DNA to exert its coactivating activity, we compared the activity of wild-type  $\alpha$ NAC and the DBD mutant,  $\alpha$ NAC $\Delta$ 69-80, on two natural target promoters, osteocalcin and mmp-9 (36). As described above,  $\alpha$ NAC $\Delta$ 69-80 could not potentiate c-Jun-mediated transcription from the OCN-Luc template (Fig. 5). Transcription from the mmp-9 promoter is induced by c-Jun, and wild-type  $\alpha$ NAC potentiates this activity (Fig. 5, bars 7 to 10) (36). Transfection of  $\alpha$ NAC $\Delta$ 69-80 by itself led to an increase in MMP9-Luc expression. Interestingly, the DBD-deleted mutant of  $\alpha$ NAC potently coactivated c-Jun-dependent transcription from the mmp-9 promoter (Fig. 5, bar 12). We interpret these data to mean that the  $\alpha$ NAC DNA-binding activity is not always necessary for coactivation,




FIG. 3. Coactivation of c-Jun-dependent osteocalcin gene transcription requires the  $\alpha$ NAC DBD. (A) Transient transfection assays were set up as described in the legend to Fig. 1. The recombinant  $\alpha$ NAC $\Delta$ 69-80 protein, devoid of DNA-binding activity, did not potentiate the activity of c-Jun. \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ . (B) The expression of the recombinant proteins was monitored by Western blot assay using the antibodies (Ab) listed above each panel. Probing with anti-TBP served as a loading control. Note that FLAG- $\alpha$ NAC $\Delta$ 69-80 migrates at the same position as endogenous  $\alpha$ NAC in SDS-PAGE, so that the band detected by the anti- $\alpha$ NAC antibody (third panel, lanes 5 and 6) represents the combined signal of endogenous  $\alpha$ NAC and FLAG- $\alpha$ NAC $\Delta$ 69-80.

but that it is a specific requirement for the potentiation of c-Jun-dependent transcription from the osteocalcin promoter.

**The  $\alpha$ NAC-DNA interaction occurs in vivo.** We used chromatin immunoprecipitation to determine if  $\alpha$ NAC occupies its cognate binding site on the osteocalcin promoter in living cells expressing osteocalcin. Wild-type osteoblastic MC3T3-E1 cells or MC3T3-E1 cells stably transfected with pSI-NAC-Flag or FLAG- $\alpha$ NAC $\Delta$ 69-80 were grown for 14 or 21 days postconfluence in the presence of ascorbic acid and beta-glycerophosphate. The expression of the wild-type or fusion proteins was monitored by immunoblotting (Fig. 6B). Note that FLAG- $\alpha$ NAC $\Delta$ 69-80 migrates at the same position as endogenous  $\alpha$ NAC in SDS-PAGE, so that the band detected by the anti- $\alpha$ NAC antibody, shown in Fig. 6B, lane 3, represents the combined signal of endogenous  $\alpha$ NAC and FLAG- $\alpha$ NAC $\Delta$ 69-80. Osteocalcin gene expression can readily be observed after 14 days in culture under the conditions used (15) (Fig. 6C). DNA was cross-linked to proteins using formaldehyde, and sonicated chromatin from whole-cell lysates was coimmunoprecipitated

using specific or negative control antibodies. DNA fragments that coprecipitated with the target proteins were purified upon reversal of protein/DNA cross-links and used as templates for PCRs with osteocalcin-specific primers. As a positive control for the assay, we used antibodies directed against Runx2/Cbfa1 and previously published primer pairs (42). The 350-bp amplicon diagnostic of Runx2/Cbfa1 binding to the osteocalcin promoter (42) was readily observed (Fig. 6A and D, lanes 1 and 2).

Cross-linked DNA was then immunoprecipitated using anti- $\alpha$ NAC or anti-Flag antibodies and amplified using primer pairs that flank the  $\alpha$ NAC binding site within the osteocalcin proximal promoter. The diagnostic 151-bp amplicon could be observed using both antibodies (Fig. 6A, lanes 5 to 8), and the amount of amplified DNA correlated with osteocalcin gene expression (Fig. 6A and C). No DNA was amplified when nonspecific IgGs were used for immunoprecipitation (Fig. 6A, lane 4). Similarly, the anti-Flag antibody did not immunopre-




FIG. 4. Coactivation of c-Jun-dependent osteocalcin gene transcription requires the  $\alpha$ NAC binding site on the promoter. Transient transfection assays were performed as described in the legend to Fig. 1. (A) Reporters used included the wild-type osteocalcin promoter driving luciferase (OCN-Luc) or a mutated osteocalcin promoter in which the  $\alpha$ NAC binding site was deleted (OCN-Luc  $\Delta$ BDG; the deletion covered from -32 to -60 relative to the transcription start site). (B) Reporters used included OCN-Luc and a mutated osteocalcin promoter in which the  $\alpha$ NAC binding site was mutated by site-specific mutagenesis (OCN-Luc mut BDG; the engineered mutation was 5'-GCACgGgGTAG-3').  $\alpha$ NAC did not potentiate the activity of c-Jun when its binding site was mutated or deleted from the promoter. \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .




FIG. 5. αNAC DNA-binding activity is specifically required for c-Jun-dependent osteocalcin gene transcription. Transient transfection assays were set up as described in the legend to Fig. 1. Two c-Jun responsive promoters were used as reporter constructs: the wild-type osteocalcin promoter (OCN-Luc) or the proximal 670 bp of the mmp-9 gene promoter (MMP9-Luc). Wild-type αNAC could potentiate the activity of c-Jun on both promoters, but the DNA-binding domain-deleted αNAC mutant (αNACΔ69-80) was active only on the MMP9-Luc template. \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .

precipitate DNA from untransfected MC3T3-E1 cells at 21 days postconfluence (lane 9). As an additional negative control, primer pairs selected from the osteocalcin coding sequence were selected. These primers did not amplify chromatin immunoprecipitated with either the anti-αNAC or anti-Flag antibodies (data not shown).

MC3T3-E1 cells were also stably transfected with the Flag epitope-tagged DBD-deleted αNAC mutant, αNACΔ69-80 (Fig. 6B, lane 3). In those transfectants, an osteocalcin promoter fragment was coimmunoprecipitated with the endogenous wild-type αNAC (Fig. 6D, lane 3), while the anti-Flag antibody, which precipitated αNACΔ69-80 (not shown), did not coimmunoprecipitate osteocalcin chromatin (Fig. 6D, lane 4).

These data show that in living osteoblastic cells expressing osteocalcin, αNAC occupies its cognate binding element. They further confirm that the αNACΔ69-80 deletion mutant is devoid of DNA-binding activity.

**Inhibition of endogenous αNAC expression affects osteocalcin promoter activity.** To confirm the relevance of αNAC in the control of osteocalcin gene transcription, we inhibited endogenous αNAC expression using RNA interference. These experiments were performed using a subclone of MC3T3-E1 preosteoblasts exhibiting high differentiation/mineralization potential that has been stably transfected with a luciferase reporter gene under the control of the 1.3-kb mouse osteocalcin promoter fragment (46). The transcriptional control of this stably integrated reporter allele was shown to be identical to that of the endogenous gene (46). Specific siRNAs for αNAC




FIG. 6. αNAC binds the osteocalcin gene promoter in living cells expressing osteocalcin. Wild-type osteoblastic MC3T3-E1 cells or MC3T3-E1 cells stably transfected with pSI-NAC-Flag (A) or the Flag epitope-tagged DBD-deleted αNAC mutant, αNACΔ69-80 (D), were grown for 14 (panel A) or 21 (panels A and D) days postconfluence in the presence of ascorbic acid and beta-glycerophosphate. Immunoprecipitation assays were performed with formaldehyde-cross-linked chromatin and antibodies against Runx2/Cbfa1, αNAC, or the Flag epitope. Ethidium bromide-stained agarose gels of PCR products obtained with primers flanking the Runx2/Cbfa1 binding site (lanes 1 and 2) or the αNAC binding site (lanes 3 to 9) within the mouse osteocalcin gene promoter are shown. Input, amplification of DNA prior to immunoprecipitation; IgG, immunoglobulin G; I.P., immunoprecipitate; M, molecular size markers. (B) Immunoblot probed with the anti-αNAC antibody that shows expression levels of endogenous and FLAG-tagged αNAC proteins. Note that FLAG-αNACΔ69-80 migrates at the same position as endogenous αNAC in SDS-PAGE, so that the band detected by the anti-αNAC antibody (lane 3) represents the combined signal of endogenous αNAC and FLAG-αNACΔ69-80. (C) Northern blot showing OCN mRNA expression. 28S, ribosomal 28S RNA used to monitor loading.

inhibited 90% of the  $\alpha$ NAC mRNA when quantified by real-time reverse transcription-PCR (Fig. 7A) and considerably reduced  $\alpha$ NAC protein expression over the duration of the experiment (Fig. 7B). The efficiency of the  $\alpha$ NAC siRNA in inhibiting its target was compared to that of an unrelated control siRNA (Fig. 7A and B, lane 2) or to the transfection reagent alone (Fig. 7B, lane 1). We next assessed the impact of  $\alpha$ NAC siRNA knock-down on osteocalcin gene transcription. Treatment of cells with the control siRNA affected osteocalcin expression, which was lower in transfected cells than in untransfected controls (relative expression was calculated as 26%) (Fig. 7A and C). This could be due to the experimental conditions, which included the subculturing of confluent cells into sparse cultures combined with treatment with the transfection reagent. Nevertheless, treatment of cells with the specific  $\alpha$ NAC siRNA that inhibited  $\alpha$ NAC mRNA and protein expression further repressed both endogenous osteocalcin mRNA levels (Fig. 7A) and the transcription of the osteocalcin promoter-controlled luciferase reporter (Fig. 7C). The effect of the  $\alpha$ NAC siRNA treatment on endogenous osteocalcin expression nearly reached statistical significance ( $P = 0.0512$ ) (Fig. 7A), while its impact on the transcription of the reporter allele was highly significant (Fig. 7C). These data establish the physiological relevance of endogenous  $\alpha$ NAC as a regulator of osteocalcin gene transcription in osteoblastic cells.

#### DISCUSSION

We have previously shown that  $\alpha$ NAC functions as a c-Jun coactivator (30, 36–38). The cloning of  $\alpha$ NAC as a differentially expressed gene product in terminally differentiated osteoblasts (47) and the expression of the  $\alpha$ NAC protein in mineralizing osteoblasts at the ossification centers of developing embryos (30) suggested that  $\alpha$ NAC should be involved in some aspects of the regulation of gene transcription in differentiated bone-forming cells. We have now identified the osteocalcin gene as a natural target gene for  $\alpha$ NAC's coactivating function. Osteocalcin encodes a bone-specific protein induced in osteoblasts with the onset of mineralization at late stages of differentiation (32). Interestingly, we have found that the regulation of osteocalcin gene transcription by  $\alpha$ NAC specifically required the previously identified DNA-binding activity of  $\alpha$ NAC (48), and we have mapped the  $\alpha$ NAC DNA-binding domain between amino acid residues 69 and 80. Confirming the *in vitro* assays, we showed that  $\alpha$ NAC binds the osteocalcin proximal promoter region in differentiated osteoblastic cells expressing osteocalcin and that specific inhibition of  $\alpha$ NAC by RNA interference affects osteocalcin promoter activity.

Functional AP-1 binding sites have been characterized for the human (16, 35, 41) and rat (2, 5, 28, 33, 34) osteocalcin promoters. Transcriptional induction of the murine osteocalcin promoter by AP-1 family members has also been reported (40). The precise mouse osteocalcin AP-1 response element remains to be characterized, but we speculated that regions from the mouse gene showing homology to characterized AP-1 elements in the promoter of the osteocalcin gene from other species could be functional sites. The most likely candidate sequence would correspond to the "OC box 1" between nucleotides -75 and -98, which is 100% homologous between rat and mouse. The rat "OC box 1" sequence was shown to bind AP-1 molecules (34). Interestingly, the  $\alpha$ NAC binding site that




FIG. 7. Inhibition of endogenous  $\alpha$ NAC expression by RNA interference affects osteocalcin promoter activity. MC3T3-E1 cells stably transfected with a luciferase reporter gene under the control of the 1.3-kb mouse osteocalcin promoter fragment (46) were transfected with a control, unrelated siRNA, or an siRNA directed against  $\alpha$ NAC. (A) Expression of the endogenous  $\alpha$ NAC or osteocalcin mRNAs was monitored by real-time PCR. \*\*\*,  $P < 0.001$ . (B) Expression of the endogenous  $\alpha$ NAC protein was assessed by immunoblotting with the anti- $\alpha$ NAC antibody. Lane 1, treatment with the transfection reagent alone; lane 2, transfection with the control siRNA; lane 3, transfection with the  $\alpha$ NAC siRNA. Staining of the membrane with Ponceau red (bottom panel) was used to monitor for even loading of each lane on the gel. (C) Expression of the reporter luciferase gene under the control of the osteocalcin promoter was monitored with a luminometer. The control bar represents expression measured in the presence of the transfection reagent alone. \*\*,  $P < 0.01$ ; Ctrl siRNA, control siRNA. Treatment of cells with the specific  $\alpha$ NAC siRNA repressed both endogenous osteocalcin mRNA levels and the transcription of the osteocalcin promoter-controlled luciferase reporter.

we have identified is adjacent to "OC box 1." While recombinant c-Jun did not bind the OC box 1 by itself (Fig. 2C) (34), a binding complex that contained c-Jun was detected when the transcription factor and coactivator were incubated together with the probe (Fig. 2C). We propose that the binding of c-Jun to its response element on the osteocalcin promoter requires  $\alpha$ NAC, which has been previously shown to stabilize the binding of c-Jun homodimers on canonical AP-1 sites (30). This model would explain why previous efforts to detect homodimeric c-Jun binding to the osteocalcin promoter were unsuccessful, since they did not include  $\alpha$ NAC in the binding reaction. Further studies are under way to precisely delineate the c-Jun binding site and define the molecular determinants of the c-Jun- $\alpha$ NAC interaction on the mouse osteocalcin gene promoter.

In differentiated rat osteoblasts, Fra-2/JunD heterodimers were identified as the major AP-1 complexes (28, 29). Our results show that the mouse osteocalcin gene promoter can respond to c-Jun. It remains to be determined whether the transfected c-Jun protein dimerized with endogenous Fos family members to activate osteocalcin gene transcription. Dimerization with c-Fos appears unlikely, as we have previously shown that  $\alpha$ NAC cannot potentiate the activity of the c-Fos/c-Jun heterodimer (30). Potential c-Jun dimerization partners would include Fra-1 or  $\Delta$ FosB, which have been shown to play functional roles in osteoblasts in the regulation of bone mass accrual (21, 23, 39, 40, 43). We favor the possibility that the c-Jun homodimer regulates osteocalcin gene transcription and that this effect is maximized in the presence of the c-Jun coactivator,  $\alpha$ NAC. This interpretation could be formally tested using the recently described expression vectors for single-chain tethered AP-1 dimers (4).

Our results confirm the previously reported specific DNA-binding activity of  $\alpha$ NAC (48). This contrasts with published work claiming that the nucleic acid-binding activity of NAC subunits is nonspecific (6). These studies also utilized recombinant  $\alpha$ NAC purified from bacteria, although they were purified with a different fusion protein system. We cannot find obvious reasons for the discrepancies between the results obtained in each case. The binding element that we identified herein within the osteocalcin promoter region matches the consensus sequence characterized with the PCR-based technique involving selection and amplification of the binding site (48). The  $\alpha$ NAC binding site in the osteocalcin promoter is fairly conserved among species (see the promoter sequence comparisons in reference 13), but the functionality of the homologous sequences from the rat and human promoters remains to be tested. It will be interesting to determine whether other genes contain similar sequence elements within their regulatory regions, although preliminary data suggest that homologous sequences are rare within the available databases (not shown).

We observed that  $\alpha$ NAC's DNA-binding activity was required for osteocalcin gene coactivation but was dispensable for the potentiation of c-Jun-dependent transcription of the mmp-9 gene. This raises the interesting possibility that  $\alpha$ NAC may be targeted to the osteocalcin promoter to achieve an increased specificity for gene transcription in differentiated osteoblasts. Such a mechanism has already been described for the B-cell-specific coactivator Bob-1 (9, 18).

Chromatin immunoprecipitation demonstrated that  $\alpha$ NAC occupied its cognate binding site in intact osteoblasts expressing osteocalcin. In nonexpressing cells, several mechanisms could operate. The coactivator might be prevented from contacting its binding element either by the inaccessibility of the chromatin or by posttranslational regulation. The first hypothesis is supported by the well-characterized role of chromatin-modifying complexes in the regulation of gene transcription (31). The second hypothesis is supported by studies showing that the activity of coactivators can be regulated by protein kinases. Phosphorylation of residue Ser184 is essential for inducible activation by the coactivator Bob-1 (49). CBP contains a signal-regulated domain required for stimulation of transcription; phosphorylation of this domain is controlled by nuclear calcium and calcium/calmodulin-dependent protein kinase IV (10, 20). The histone acetyltransferase activity of CBP is also regulated upon phosphorylation by p44 MAPK/ERK1 (1). We have shown that differential phosphorylation of  $\alpha$ NAC controls its half-life (36) and its nuclear entry (37). It is possible that differential phosphorylation might regulate its DNA-binding activity. Indeed, computer-based analysis identifies residue Ser70 within the DNA-binding domain as a potential phosphoacceptor site (data not shown).

Alternatively,  $\alpha$ NAC might occupy its cognate binding site even in nonexpressing cells. In this scenario, posttranslational modifications such as phosphorylation could function to allow  $\alpha$ NAC to recruit transcriptional repressors that would maintain osteocalcin gene expression as silent. The induction of osteocalcin expression would require a different pattern of posttranslational modifications of the  $\alpha$ NAC protein that could then function as a coactivator of osteocalcin transcription. Additional studies are required to distinguish between these various possibilities.

The osteocalcin gene promoter has been extensively studied. It is modularly organized and contains several positive and negative regulatory elements (26). Our results have identified yet another regulatory sequence within the proximal osteocalcin promoter region, the  $\alpha$ NAC binding site. The down-regulation of osteocalcin promoter activity measured when endogenous  $\alpha$ NAC levels are reduced in osteoblastic cells confirms the physiological relevance of  $\alpha$ NAC in the control of osteocalcin gene transcription. It will prove interesting to characterize the functional interplay between the various transcriptional regulators that control osteocalcin promoter activity in differentiating osteoblasts.

#### ACKNOWLEDGMENTS

We thank Gérard Karsenty (Baylor College of Medicine) and Shoukat Dedhar (University of British Columbia) for providing expression vectors and reporter plasmids. We are indebted to Renny T. Franceschi (University of Michigan) for his generous gift of the MC3T3-E1 subclone stably transfected with the osteocalcin-luciferase reporter and for tips on the ChIP assay. We are grateful to McGill University and the Genome Quebec Innovation Centre for allowing repeated usage of the real-time PCR instrument. Mark Lepik and Guylaine Bédard prepared the figures.

This work was supported by the Shriners of North America.

#### REFERENCES

1. Ait-Si-Ali, S., D. Carlisi, S. Ramirez, L. C. Upegui-Gonzalez, A. Duquet, P. Robin, B. Rudkin, A. Harel-Bellan, and D. Trouche. 1999. Phosphorylation by p44 MAP kinase/ERK1 stimulates CBP histone acetyl transferase activity in vitro. *Biochem. Biophys. Res. Commun.* **262**:157-162.



2. Aslam, F., L. McCabe, B. Frenkel, A. J. van Wijnen, G. S. Stein, J. B. Lian, and J. L. Stein. 1999. AP-1 and vitamin D receptor (VDR) signaling pathways converge at the rat osteocalcin VDR element: requirement for the internal activating protein-1 site for vitamin D-mediated trans-activation. *Endocrinology* **140**:63–70.
3. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1993. Current protocols in molecular biology. John Wiley and Sons, New York, N.Y.
4. Bakiri, L., K. Matsuo, M. Wisniewska, E. F. Wagner, and M. Yaniv. 2002. Promoter specificity and biological activity of tethered AP-1 dimers. *Mol. Cell. Biol.* **22**:4952–4964.
5. Banerjee, C., J. L. Stein, A. J. Van Wijnen, B. Frenkel, J. B. Lian, and G. S. Stein. 1996. Transforming growth factor-beta 1 responsiveness of the rat osteocalcin gene is mediated by an activator protein-1 binding site. *Endocrinology* **137**:1991–2000.
6. Beatrix, B., H. Sakai, and M. Wiedmann. 2000. The alpha and beta subunit of the nascent polypeptide-associated complex have distinct functions. *J. Biol. Chem.* **275**:37838–37845.
7. Candelieri, G. A., P. W. Jurutka, M. R. Haussler, and R. St-Arnaud. 1996. A composite element binding the vitamin D receptor, retinoid X receptor  $\alpha$ , and a member of the CTF/NF-1 family of transcription factors mediates the vitamin D responsiveness of the *c-fos* promoter. *Mol. Cell. Biol.* **16**:584–592.
8. Celeste, A. J., V. Rosen, J. L. Buecker, R. Kriz, E. A. Wang, and J. M. Wozney. 1986. Isolation of the human gene for bone gla protein utilizing mouse and rat cDNA clones. *EMBO J.* **5**:1885–1890.
9. Cepek, K. L., D. I. Chasman, and P. A. Sharp. 1996. Sequence-specific DNA binding of the B-cell-specific coactivator OCA-B. *Genes Dev.* **10**:2079–2088.
10. Chawla, S., G. E. Hardingham, D. R. Quinn, and H. Bading. 1998. CBP: a signal-regulated transcriptional coactivator controlled by nuclear calcium and CaM kinase IV. *Science* **281**:1505–1509.
11. Courey, A. J., and R. Tjian. 1988. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. *Cell* **55**:887–898.
12. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res.* **11**:1475–1489.
13. Ducy, P., and G. Karsenty. 1995. Two distinct osteoblast-specific *cis*-acting elements control expression of a mouse osteocalcin gene. *Mol. Cell. Biol.* **15**:1858–1869.
14. Ducy, P., R. Zhang, V. Geoffroy, A. L. Ridall, and G. Karsenty. 1997. *Osf2/Cbfa1*: a transcriptional activator of osteoblast differentiation. *Cell* **89**:747–754.
15. Franceschi, R. T., and B. S. Iyer. 1992. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. *J. Bone Miner. Res.* **7**:235–246.
16. Goldberg, D., P. Polly, J. A. Eisman, and N. A. Morrison. 1996. Identification of an osteocalcin gene promoter sequence that binds AP1. *J. Cell. Biochem.* **60**:447–457.
17. Green, M. R. 2000. TBP-associated factors (TAFII)s: multiple, selective transcriptional mediators in common complexes. *Trends Biochem. Sci.* **25**:59–63.
18. Gstaiger, M., O. Georgiev, H. van Leeuwen, P. van der Vliet, and W. Schaffner. 1996. The B cell coactivator Bob1 shows DNA sequence-dependent complex formation with Oct-1/Oct-2 factors, leading to differential promoter activation. *EMBO J.* **15**:2781–2790.
19. Gum, R., E. Lengyel, J. Juarez, J. H. Chen, H. Sato, M. Seiki, and D. Boyd. 1996. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. *J. Biol. Chem.* **271**:10672–10680.
20. Hu, S. C., J. Chrivia, and A. Ghosh. 1999. Regulation of CBP-mediated transcription by neuronal calcium signaling. *Neuron* **22**:799–808.
21. Jochum, W., J. P. David, C. Elliott, A. Wutz, H. Plenk, Jr., K. Matsuo, and E. F. Wagner. 2000. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. *Nat. Med.* **6**:980–984.
22. Karsenty, G., and E. F. Wagner. 2002. Reaching a genetic and molecular understanding of skeletal development. *Dev. Cell* **2**:389–406.
23. Kveiborg, M., G. Sabatakos, R. Chiusaroli, M. Wu, W. M. Philbrick, W. C. Horne, and R. Baron. 2004.  $\Delta$ FosB induces osteosclerosis and decreases adipogenesis by two independent cell-autonomous mechanisms. *Mol. Cell. Biol.* **24**:2820–2830.
24. Laumen, H., P. J. Nielsen, and T. Wirth. 2000. The BOB. 1/OBF. 1 coactivator is essential for octamer-dependent transcription in B cells. *Eur. J. Immunol.* **30**:458–469.
25. Lian, J. B., and G. S. Stein. 2003. Runx2/Cbfa1: a multifunctional regulator of bone formation. *Curr. Pharm. Des.* **9**:2677–2685.
26. Lian, J. B., G. S. Stein, J. L. Stein, and A. J. van Wijnen. 1998. Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. *J. Cell. Biochem. Suppl.* **31**:62–72.
27. Lian, J. B., J. L. Stein, G. S. Stein, A. J. van Wijnen, M. Montecino, A. Javed, S. Gutierrez, J. Shen, S. K. Zaidi, and H. Drissi. 2003. Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. *Connect. Tissue Res.* **44**(Suppl. 1):141–148.
28. McCabe, L. R., C. Banerjee, R. Kundu, R. J. Harrison, P. R. Dobner, J. L. Stein, J. B. Lian, and G. S. Stein. 1996. Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: role of Fra-2 and Jun D during differentiation. *Endocrinology* **137**:4398–4408.
29. McCabe, L. R., M. Kockx, J. Lian, J. Stein, and G. Stein. 1995. Selective expression of fos- and jun-related genes during osteoblast proliferation and differentiation. *Exp. Cell Res.* **218**:255–262.
30. Moreau, A., W. V. Yotov, F. H. Glorieux, and R. St-Arnaud. 1998. Bone-specific expression of the alpha chain of the nascent polypeptide-associated complex, a coactivator potentiating c-Jun-mediated transcription. *Mol. Cell. Biol.* **18**:1312–1321.
31. Narlikar, G. J., H. Y. Fan, and R. E. Kingston. 2002. Cooperation between complexes that regulate chromatin structure and transcription. *Cell* **108**:475–487.
32. Owen, T. A., M. Aronow, V. Shalhoub, L. M. Barone, L. Wilming, M. S. Tassinari, M. B. Kennedy, S. Pockwinse, J. B. Lian, and G. S. Stein. 1990. Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. *J. Cell. Physiol.* **143**:420–430.
33. Owen, T. A., R. Bortell, V. Shalhoub, A. Heinrichs, J. L. Stein, G. S. Stein, and J. B. Lian. 1993. Postproliferative transcription of the rat osteocalcin gene is reflected by vitamin D-responsive developmental modifications in protein-DNA interactions at basal and enhancer promoter elements. *Proc. Natl. Acad. Sci. USA* **90**:1503–1507.
34. Owen, T. A., R. Bortell, S. A. Yocum, S. L. Smock, M. Zhang, C. Abate, V. Shalhoub, N. Aronin, K. L. Wright, A. J. van Wijnen, et al. 1990. Coordinate occupancy of AP-1 sites in the vitamin D-responsive and CCAAT box elements by Fos-Jun in the osteocalcin gene: model for phenotype suppression of transcription. *Proc. Natl. Acad. Sci. USA* **87**:9990–9994.
35. Ozono, K., J. Liao, S. A. Kerner, R. A. Scott, and J. W. Pike. 1990. The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. *J. Biol. Chem.* **265**:21881–21888.
36. Quelo, I., O. Akhouayri, J. Prud'homme, and R. St-Arnaud. 2004. GSK3beta-dependent phosphorylation of the alphaNAC coactivator regulates its nuclear translocation and proteasome-mediated degradation. *Biochemistry* **43**:2906–2914.
37. Quelo, I., C. Gauthier, G. E. Hannigan, S. Dedhar, and R. St-Arnaud. 2004. Integrin-linked kinase regulates the nuclear entry of the c-Jun coactivator alpha-NAC and its coactivation potency. *J. Biol. Chem.* **279**:43893–43899.
38. Quelo, I., M. Hurtubise, and R. St-Arnaud. 2002. alphaNAC requires an interaction with c-Jun to exert its transcriptional coactivation. *Gene Expr.* **10**:255–262.
39. Roschger, P., K. Matsuo, B. M. Misof, W. Tesch, W. Jochum, E. F. Wagner, P. Fratzl, and K. Klaushofer. 2004. Normal mineralization and nanostructure of sclerotic bone in mice overexpressing Fra-1. *Bone* **34**:776–782.
40. Sabatakos, G., N. A. Sims, J. Chen, K. Aoki, M. B. Kelz, M. Amling, Y. Bouali, K. Mukhopadhyay, K. Ford, E. J. Nestler, and R. Baron. 2000. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. *Nat. Med.* **6**:985–990.
41. Schule, R., K. Umeson, D. J. Mangelsdorf, J. Bolado, J. W. Pike, and R. M. Evans. 1990. Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene. *Cell* **61**:497–504.
42. Shen, J., M. Montecino, J. B. Lian, G. S. Stein, A. J. van Wijnen, and J. L. Stein. 2002. Histone acetylation in vivo at the osteocalcin locus is functionally linked to vitamin D-dependent, bone tissue-specific transcription. *J. Biol. Chem.* **277**:20284–20292.
43. Sims, N. A., G. Sabatakos, J. S. Chen, M. B. Kelz, E. J. Nestler, and R. Baron. 2002. Regulating DeltaFosB expression in adult Tet-Off-DeltaFosB transgenic mice alters bone formation and bone mass. *Bone* **30**:32–39.
44. Sudo, H., H. A. Kodama, Y. Amagai, S. Yamamoto, and S. Kasai. 1983. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. *J. Cell Biol.* **96**:191–198.
45. Wiedmann, B., H. Sakai, T. A. Davis, and M. Wiedmann. 1994. A protein complex required for signal-sequence-specific sorting and translocation. *Nature* **370**:434–440.
46. Xiao, G., Y. Cui, P. Ducy, G. Karsenty, and R. T. Franceschi. 1997. Ascorbic acid-dependent activation of the osteocalcin promoter in MC3T3-E1 preosteoblasts: requirement for collagen matrix synthesis and the presence of an intact OSE2 sequence. *Mol. Endocrinol.* **11**:1103–1113.
47. Yotov, W. V., A. Moreau, and R. St-Arnaud. 1998. The alpha chain of the nascent polypeptide-associated complex functions as a transcriptional coactivator. *Mol. Cell. Biol.* **18**:1303–1311.
48. Yotov, W. V., and R. St-Arnaud. 1996. Differential splicing-in of a proline-rich exon converts alphaNAC into a muscle-specific transcription factor. *Genes Dev.* **10**:1763–1772.
49. Zwilling, S., A. Dieckmann, P. Pfisterer, P. Angel, and T. Wirth. 1997. Inducible expression and phosphorylation of coactivator BOB. 1/OBF. 1 in T cells. *Science* **277**:221–225.